tiprankstipranks
Monte Rosa Therapeutics (GLUE)
NASDAQ:GLUE
US Market

Monte Rosa Therapeutics (GLUE) Income Statement

70 Followers

Monte Rosa Therapeutics Income Statement

Last quarter (Q3 2023), Monte Rosa Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Monte Rosa Therapeutics's net income was $-34.71M. See Monte Rosa Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19
Total Revenue
---$ 0.00$ 0.00
Cost of Revenue
-----
Gross Profit
-----
Operating Expense
$ 75.96M$ 112.38M$ 72.88M$ 28.01M$ 7.99M
Operating Income
$ -139.95M$ -112.38M$ -72.88M$ -28.01M$ -7.99M
Net Non Operating Interest Income Expense
$ 8.66M$ 3.76M$ -914.00K$ 9.00K$ -1.00K
Other Income Expense
$ -720.00K$ -109.00K$ 965.00K$ -7.88M$ 255.00K
Pretax Income
$ -130.56M$ -108.05M$ -74.92M$ -35.88M$ -7.74M
Tax Provision
$ 214.00K----
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
$ -130.60M$ -108.05M$ -74.92M$ -35.88M$ -7.74M
Basic EPS
$ -2.06$ -2.30$ -2.96$ -3.22$ -0.69
Diluted EPS
$ -1.55$ -2.30$ -2.96$ -3.22$ -0.69
Basic Average Shares
$ 195.82M$ 47.23M$ 25.00M$ 11.14M$ 11.14M
Diluted Average Shares
$ 195.82M$ 47.23M$ 25.00M$ 11.14M$ 11.14M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
$ 75.96M$ 112.38M$ 72.88M$ 28.01M$ 7.99M
Net Income From Continuing And Discontinued Operation
$ -131.13M$ -108.50M$ -74.92M$ -35.88M$ -7.74M
Normalized Income
$ -55.26M$ -85.47M-$ -35.68M$ -7.72M
Interest Expense
----$ 1.00K
EBIT
$ -134.69M$ -108.03M$ -74.01M$ -28.01M$ -7.74M
EBITDA
$ -64.50M$ -104.33M$ -71.91M$ -27.47M$ -7.67M
Currency in USD

Monte Rosa Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis